Look up the acronym explanations below Table 1. To spare you some details from the paper patients were enrolled in the study but the three groups you see 1-16, 17-30, 31-36. All treated patients were hospitalized in the Mditerrane Infection University Hospital Institute in Marseille. The non-treated patients were from other proximal centers. Can we conclude that the use of Hydroxychloroquine in two regimens (with or without azithromycin) changes the outcomes of the treatment on the 6 th day (D6) relative to the outcomes of the patients who are not treated with the above regimens. Outcomes are split in three categories: NEG, POS, ND (non-determined). Any numbers in the D6 column should be treated as POS results, as they represent viral load. Patients 1-17 received only standard of care and none of the two regimens.

Supplementary Table 1 Paint la Ape Ses Clinical status 01 Hydroxychloroquine samt DO D3 DI DS D6 (years) Time between One of symptoms and inclusion (days) Hydroxychloroque serum concentration pg/ml (day of dosage) Azturom ycin NEG NEG 1 2 3 4 No No No No 31 26 26 14 - 23 33 24 POS ND 10 12 14 10 20 65 06 69 62 66 75 23 65 16 6 2 8 9 10 11 12 13 14 15 16 POS M F F M M F M M F F F F F M F F Asymptomatic Asymptomatic Asymptomatic URTI URTI URTI LRT LRTI URTI URTI URTI URTI URTI URTI URTI 4 2 Unknown 2 10 0 3 3 Unknown 2 3 6 No No Na No No No No No No Na Ne No No No No No No No No No No No POS 28 POS POS POS POS ND POS POS ND POS NEG ND 31 NEG 24 ND ND ND ND ND ND ND ND ND ND ND NEG 1 22 33 27 ND ND ND ND ND ND ND ND ND POS ND NEO 34 NEG NEG 31 ND ND POS ND ND ND ND ND POS POS POS NEG 27 NEG NEG POS 26 POS POS ND POS POS POS ND NE ND NEG NEG 26 32 29 POS 30 POS POS POS ND ND POS ND ND ND POS POS POS POS POS POS ND ND No No No No 23 6 31 NEG 3 26 NEG NEG NEG 24 NEG 1 17 18 19 20 21 22 23 24 25 26 27 28 29 30 NEG SA 25 59 59 24 81 85 0 53 63 42 87 33 AMAMA AAAAAAAAAAAAAAAAAAAA F M M F F F F F M M F F F M NEG 22 NEG NEG URTI Asymptomatic URTI Asyreptomatic URTI URTI LRTI LRTI URTI URTI URTI URTI URTI URTI Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 2 1 3 5 8 1 5 2 0.519 06) 0.462 (6) 0419 (D6 0.288 (10) 0621 (16) 0.723 006) 0.591 (16) 0.619 (6) 0.418 (16) 0515 (D6 0319000) 04506) 0.552 (DS) 0.194 D) No No No No No No No No No No No No 30 29 23 30 34 28 22 17 22 27 34 19 25 15 ND NEG 25 NEG 27 NEG 21 21 ND 28 NEG 16 30 25 29 NEG 28 NEG 19 32 30 23 28 32 30 17 NEG 26 26 NEG 25 NEG 16 34 NEG 21 21 31 NEG 17 NEG 26 NEG NEG NEG 34 NEG 52 26 15 NEG NEG 19 NEG NE 28 24 20 NEG NEG 10 ND 32 12 NEG NEG 31 ND 32 No 31 53 F LTRI 7 Yes 1.07606 28 32 48 M URTI 2 Yes 05706 23 33 So F LRTI 3 Yes 082706 Yes 30 34 M URTI 2 Yes 0381 DO Yes 27 35 54 M LRTI 6 Yes 0.366 (D) 24 36 60 M LRTI 4 Yes 0.319 (4) Yes 19 URTI upper tract respiratory infection. LRTI lower tact respiratory infection, POS porative PCR NEG negative PCR (CT valse 35). ND FCR not done 31 20 27 31 ND 31 34 29 NEG 29 ND 31 NEG NEG NEG NEG 29 NEG 34 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG Please cite this work as Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents - In Press 17 March 2020 - DOI: 10.1016/j.ijantimicag.2020.105949 The previous table is from the following preliminary study: Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non- randomized clinical trial. International Journal of Antimicrobial Agents, In Press 17 March 2020 DOI: 10.1016/j.ijantimicag.2020.105949 Look up the acronym explanations below Table 1. To spare you some details from the paper patients were enrolled in the study but the three groups you see 1-16, 17-30, 31-36. All treated patients were hospitalized in the Mditerrane Infection University Hospital Institute in Marseille. The non-treated patients were from other proximal centers. Can we conclude that the use of Hydroxychloroquine in two regimens (with or without azithromycin) changes the outcomes of the treatment on the 6th day (D6) relative to the outcomes of the patients who are not treated with the above regimens? Outcomes are split in three categories: NEG, POS, ND (non-determined). Any numbers in the D6 column should be treated as POS results, as they represent viral load. Patients 1-17 received only standard of care and none of the two regimens. Supplementary Table 1 Paint la Ape Ses Clinical status 01 Hydroxychloroquine samt DO D3 DI DS D6 (years) Time between One of symptoms and inclusion (days) Hydroxychloroque serum concentration pg/ml (day of dosage) Azturom ycin NEG NEG 1 2 3 4 No No No No 31 26 26 14 - 23 33 24 POS ND 10 12 14 10 20 65 06 69 62 66 75 23 65 16 6 2 8 9 10 11 12 13 14 15 16 POS M F F M M F M M F F F F F M F F Asymptomatic Asymptomatic Asymptomatic URTI URTI URTI LRT LRTI URTI URTI URTI URTI URTI URTI URTI 4 2 Unknown 2 10 0 3 3 Unknown 2 3 6 No No Na No No No No No No Na Ne No No No No No No No No No No No POS 28 POS POS POS POS ND POS POS ND POS NEG ND 31 NEG 24 ND ND ND ND ND ND ND ND ND ND ND NEG 1 22 33 27 ND ND ND ND ND ND ND ND ND POS ND NEO 34 NEG NEG 31 ND ND POS ND ND ND ND ND POS POS POS NEG 27 NEG NEG POS 26 POS POS ND POS POS POS ND NE ND NEG NEG 26 32 29 POS 30 POS POS POS ND ND POS ND ND ND POS POS POS POS POS POS ND ND No No No No 23 6 31 NEG 3 26 NEG NEG NEG 24 NEG 1 17 18 19 20 21 22 23 24 25 26 27 28 29 30 NEG SA 25 59 59 24 81 85 0 53 63 42 87 33 AMAMA AAAAAAAAAAAAAAAAAAAA F M M F F F F F M M F F F M NEG 22 NEG NEG URTI Asymptomatic URTI Asyreptomatic URTI URTI LRTI LRTI URTI URTI URTI URTI URTI URTI Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 2 1 3 5 8 1 5 2 0.519 06) 0.462 (6) 0419 (D6 0.288 (10) 0621 (16) 0.723 006) 0.591 (16) 0.619 (6) 0.418 (16) 0515 (D6 0319000) 04506) 0.552 (DS) 0.194 D) No No No No No No No No No No No No 30 29 23 30 34 28 22 17 22 27 34 19 25 15 ND NEG 25 NEG 27 NEG 21 21 ND 28 NEG 16 30 25 29 NEG 28 NEG 19 32 30 23 28 32 30 17 NEG 26 26 NEG 25 NEG 16 34 NEG 21 21 31 NEG 17 NEG 26 NEG NEG NEG 34 NEG 52 26 15 NEG NEG 19 NEG NE 28 24 20 NEG NEG 10 ND 32 12 NEG NEG 31 ND 32 No 31 53 F LTRI 7 Yes 1.07606 28 32 48 M URTI 2 Yes 05706 23 33 So F LRTI 3 Yes 082706 Yes 30 34 M URTI 2 Yes 0381 DO Yes 27 35 54 M LRTI 6 Yes 0.366 (D) 24 36 60 M LRTI 4 Yes 0.319 (4) Yes 19 URTI upper tract respiratory infection. LRTI lower tact respiratory infection, POS porative PCR NEG negative PCR (CT valse 35). ND FCR not done 31 20 27 31 ND 31 34 29 NEG 29 ND 31 NEG NEG NEG NEG 29 NEG 34 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG Please cite this work as Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents - In Press 17 March 2020 - DOI: 10.1016/j.ijantimicag.2020.105949 The previous table is from the following preliminary study: Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non- randomized clinical trial. International Journal of Antimicrobial Agents, In Press 17 March 2020 DOI: 10.1016/j.ijantimicag.2020.105949 Look up the acronym explanations below Table 1. To spare you some details from the paper patients were enrolled in the study but the three groups you see 1-16, 17-30, 31-36. All treated patients were hospitalized in the Mditerrane Infection University Hospital Institute in Marseille. The non-treated patients were from other proximal centers. Can we conclude that the use of Hydroxychloroquine in two regimens (with or without azithromycin) changes the outcomes of the treatment on the 6th day (D6) relative to the outcomes of the patients who are not treated with the above regimens? Outcomes are split in three categories: NEG, POS, ND (non-determined). Any numbers in the D6 column should be treated as POS results, as they represent viral load. Patients 1-17 received only standard of care and none of the two regimens